Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 8/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18745 | 0.91 | PDE10A (0.51) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3787063 | 0.83 | MEN1 (0.46) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3782566 | 0.83 | ALDH1A1 (0.49) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL3775607 | 0.82 | DHODH (0.56) | DHODHPDE10A | |
| SCHEMBL3786796 | 0.81 | DHODH (0.48) | DHODHPDE10ALMNATSHRALDH1A1 | |
| SCHEMBL3775453 | 0.81 | TACR1 (0.42) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL1759028 | 0.79 | ERN1 (0.54) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL352547 | 0.79 | PDE10A (0.50) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL29450068 | 0.79 | PDE10A (0.50) | DHODHPDE10ALMNATSHRCYP2D6 | |
| SCHEMBL2512893 | 0.77 | KDM4E (0.60) | DHODHPDE10ALMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5521171-A | COPPER COMPLEX WITH HETEROCYCLIC CARBOXYLIC ACID | SORENSON JOHN R J (US) | 1996-05-28 | — | — | US | claimed |
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1786813-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-6306846-B1 | ADMINISTERING A COPPER ORGANIC COORDINATION COMPOUND FOR TREATMENT OF ULCERS | SORENSON JOHN R J (US) | 2001-10-23 | — | — | US | disclosed |
| US-5541174-A | COORDINATION COMPOUND OF COPPER AND AN AMINO ACID | SORENSON JOHN R J (US) | 1996-07-30 | — | — | US | disclosed |
| US-5521171-A | COPPER COMPLEX WITH HETEROCYCLIC CARBOXYLIC ACID | SORENSON JOHN R J (US) | 1996-05-28 | — | — | US | disclosed |
| US-5216021-A | Copper coordination compounds | SORENSON JOHN R J (US) | 1993-06-01 | — | — | US | disclosed |
| US-5082834-A | Antiarthritic agents, coordination compounds of copper and aci d salicylates | J.R.J. SORENSON CORP. | 1992-01-21 | — | — | US | disclosed |
| US-4999347-A | Copper coordination compounds | J.R.J. SORENSON CORP. | 1991-03-12 | — | — | US | disclosed |
| US-4801593-A | VIRICIDE FOR RHINITIS VIRUS CONTAINING 2-PHENYLTETRALIN DERIVATIVE | BURROUGHS WELLCOME CO. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0025598-B1 | THE USE OF 2-PHENYLTETRALIN DERIVATIVES, OR HETEROCYCLIC ANALOGUES, IN MEDICINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-08-01 | — | — | EP | disclosed |
| US-4440754-A | COPPER COORDINATION COMPOUNDS | J.R.J. SORENSON CORP. | 1984-04-03 | — | — | US | disclosed |
| EP-0025598-A1 | The use of 2-phenyltetralin derivatives, or heterocyclic analogues, in medicine and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
| US-4221785-A | COORDINATION COMPOUND OF A COPPER SALT AND A SALICYLIC ACID OR ITS DERIVATIVE | J.R.J. SORENSON CORP. | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | DHODH 677/4885PDE10A 23/4885LMNA 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.